

**Cell Reports Medicine, Volume 2**

**Supplemental information**

**Psychotherapy-supported MDMA treatment for PTSD**

**John H. Krystal, Benjamin Kelmendi, and Ismene L. Petrakis**

## **John H. Krystal, M.D. - Financial Disclosures:**

### **The Individual Consultant Agreements listed below are less than \$10,000 per year**

Aptinyx, Inc., Atai Life Sciences, AstraZeneca Pharmaceuticals, Biogen, Idec, MA, Biomedisyn Corporation, Bionomics, Limited (Australia), Boehringer Ingelheim International, Cadent Therapeutics, Inc., Clexio Bioscience, Ltd., COMPASS Pathways, Limited, United Kingdom, Concert Pharmaceuticals, Inc., Epiodyne, Inc., EpiVario, Inc., Greenwich Biosciences, Inc., Heptares Therapeutics, Limited (UK), Janssen Research & Development, Jazz Pharmaceuticals, Inc., Otsuka America Pharmaceutical, Inc., Perception Neuroscience Holdings, Inc., Spring Care, Inc., Sunovion Pharmaceuticals, Inc., Takeda Industries, Taisho Pharmaceutical Co., Ltd.

### **Scientific Advisory Board**

Biohaven Pharmaceuticals, BioXcel Therapeutics, Inc. (Clinical Advisory Board), Cadent Therapeutics, Inc. (Clinical Advisory Board), Cerevel Therapeutics, LLC., EpiVario, Inc, Eisai, Inc., Jazz Pharmaceuticals, Inc., Lohocla Research Corporation, Novartis Pharmaceuticals Corporation, PsychoGenics, Inc., RBNC Therapeutics, Inc., Tempero Bio, Inc., Terran Biosciences.

### **Board of Directors**

Freedom Biosciences, Inc.

### **Stock**

Biohaven Pharmaceuticals, Sage Pharmaceuticals, Spring Care, Inc.

### **Stock Options**

Biohaven Pharmaceuticals Medical Sciences, EpiVario, Inc., RBNC Therapeutics, Inc., Terran Biosciences, Inc., Tempero Bio, Inc.

### **Income Greater than \$10,000**

### **Editorial Board**

Editor - Biological Psychiatry

### **Patents and Inventions**

1. Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. US Patent #:5,447,948, September 5, 1995.
2. Vladimir, Coric, Krystal, John H, Sanacora, Gerard – Glutamate Modulating Agents in the Treatment of Mental Disorders. US Patent No. 8,778,979 B2 Patent Issue Date: July 15, 2014. US Patent Application No. 15/695,164: Filing Date: 09/05/2017.
3. Charney D, Krystal JH, Manji H, Matthew S, Zarate C., Intranasal Administration of Ketamine to Treat Depression United States Patent Number: 9592207, Issue date: 3/14/2017. Licensed to Janssen Research & Development.
4. Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, Krystal, JH, Yale University “Methods for Treating Suicidal Ideation”, Patent Application No. 15/379,013 filed on December 14, 2016 by Yale University Office of Cooperative Research.
5. Arias A, Petrakis I, Krystal JH. – Composition and methods to treat addiction. Provisional Use Patent Application no.61/973/961. April 2, 2014. Filed by Yale University Office of Cooperative Research.
6. Chekroud, A., Gueorguieva, R., & Krystal, JH. “Treatment Selection for Major Depressive Disorder” [filing date 3<sup>rd</sup> June 2016, USPTO docket number Y0087.70116US00]. Provisional patent submission by Yale University.
7. Gihyun, Yoon, Petrakis I, Krystal JH – Compounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases. U. S. Provisional Patent Application No.

62/444,552, filed on January 10, 2017 by Yale University Office of Cooperative Research OCR 7088 US01.

8. Abdallah, C, Krystal, JH, Duman, R, Sanacora, G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. U.S. Provisional Patent Application No. 62/719,935 filed on August 20, 2018 by Yale University Office of Cooperative Research OCR 7451 US01

9. John Krystal, Godfrey Pearlson, Stephanie O'Malley, Marc Potenza, Fabrizio Gasparini, Baltazar Gomez-Mancilla, Vincent Malaterre. Mavoglurant in treating gambling and gaming disorders. U.S. Provisional Patent Application No. 63/125,181 filed on December 14, 2020 by Yale University Office of Cooperative Research OCR 8065 US00.

**NON Federal Research Support**

AstraZeneca Pharmaceuticals provides the drug, Saracatinib, for research related to NIAAA grant "Center for Translational Neuroscience of Alcoholism [CTNA-4]

Novartis provides the drug, Mavoglurant, for research related to NIAAA grant "Center for Translational Neuroscience of Alcoholism [CTNA-4]

**Dr. Benjamin Kelmendi** serves as member of the Scientific Advisory Board for Lobe Sciences.